What Should Investors Know About Incyte (INCY) Stock?

Incyte, a large-cap None stock, moved -0.6% this evening. Here are some facts about the company that we're keeping an eye on:

  • Incyte has logged a -35.0% 52 week change, compared to 14.0% for the S&P 500

  • INCY has an average analyst rating of buy and is -27.4% away from its mean target price of $74.41 per share

  • Its trailing earnings per share (EPS) is $1.88, which brings its trailing Price to Earnings (P/E) ratio to 28.7. The Health Care sector's average P/E ratio is None

  • The company's forward earnings per share (EPS) is $4.52 and its forward P/E ratio is 12.0

  • The company has a Price to Book (P/B) ratio of 2.45 in contrast to the Health Care sector's average P/B ratio is None

  • INCY has reported YOY quarterly earnings growth of 52.0% and gross profit margins of 0.5%

  • The company's free cash flow for the last fiscal year was $554.59 Million and the average free cash flow growth rate is 13.3%

  • Incyte's revenues have an average growth rate of 10.3% with operating expenses growing at None%. The company's current operating margins stand at 19.0%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.